Sacral neuromodulation for overactive bladder: Is it worth it?

Magdy Hassouna, MD, PhD, FRCSC

Department of Surgery, University of Toronto, Toronto, ON

The timing of this manuscript is good since the use of anticholinergics to treat OAB often delays the offering of SNM early to those patients before the OAB condition becomes irreversible or even difficult to treat with SNM.

The new era of oral beta-adrenergic agonists is promising better control of OAB symptoms with less side effects than anticholinergics. Whether this group of drugs will help SNM remains to be tested on OAB.

Competing interests: None declared.

Reference


Correspondence: Dr. Magdy Hassouna, University Health Network, Suite 3-130, 610 University Ave., Toronto, ON M5G 2M9; fax: 416-603-1961; magdy.hassouna@uhn.on.ca